Inovio’s Emergency Funding Move Sends Shares Plunging
Published on 11/12/2025 at 14:03 | Redaktion boerse-global.de
Biotechnology firm Inovio Pharmaceuticals has triggered investor alarm with a deeply discounted stock offering that aims to secure crucial funding. The emergency capital raise comes at a substantial cost to existing shareholders, who face significant dilution as the company fights to maintain operations.
Inovio’s latest financial reports reveal a precarious position. During the third quarter, the company consumed $21.2 million in cash while reporting cash reserves of just $50.8 million. This burn rate indicated the company would have faced insolvency by the second quarter of 2026 without immediate intervention.
The newly announced offering involves 13.1 million shares priced at $1.90 each—a substantial discount to previous trading levels. This financing round is expected to generate Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
